(CercleFinance.com) – Guerbet today unveils its strategic priorities for 2023 in a complex international context that it “demanding and promising”. Guerbet therefore intends to capitalize on its core target activities and its established positions.
In the diagnostic imaging market, where it generates almost 90% of its turnover, Guerbet believes that 2023 will mark an important milestone with the marketing in the United States of the first batches of the brand new EluciremTM product.
In Europe, the review by the European Medicines Agency (EMA) is expected in the second half.
In interventional imaging, Guerbet is betting on the commercial development and expansion of the applications of Lipiodol – a standard in the treatment of liver cancer. ‘The development potential for new innovative indications appears significant’, indicates the group, referring in particular to the treatment of musculoskeletal disorders, venous diseases or even post-surgery disorders and cancer.
Guerbet also plans to gradually withdraw from its micro-catheter activities historically housed within Accurate Medical Therapeutics and to sell the Occlugel technology acquired in 2018.
Finally, in the field of artificial intelligence, Guerbet indicates that it has obtained “very promising” results in 2022 in the detection of liver damage and prostate cancer.
‘The commercial development of the solutions will benefit from the licensing agreement which should be concluded in the first half of 2023 with the company
Intrasense’, adds the group.
Ultimately, Guerbet aims to create ‘a major player in artificial intelligence applied to medical imaging in oncology’.